NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting – Yahoo Finance

Share Article

Vancouver, British Columbia–(Newsfile Corp. – September 8, 2022) –  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium (MHSRS) on September 12-15, 2022 and will also present an oral presentation at the 61st International Spinal Cord Society (ISCoS) Annual Scientific Meeting on September 17, 2022.
NervGen’s Director of Research, Dr. Marc DePaul, will present a poster at MHSRS outlining some of the preclinical data related to NervGen’s lead drug candidate NVG-291. At the ISCoS meeting, NervGen’s Chief Medical Officer, Dr. Dan Mikol, will give a presentation providing an overview on the ongoing Phase 1 study, as well as presenting the study design for the upcoming Phase 1b/2a clinical trial in spinal cord injury.
About Military Health System Research Symposium (MHSRS)
The MHSRS is the Department of Defense’s foremost scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and development. The MHSRS is the premier military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter. The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives.
About International Spinal Cord Society (ISCoS) Annual Scientific Meeting
ISCoS promotes the highest standard of care in the practice of spinal cord injury for men, women and children throughout the world. Their purpose is to study all problems relating to traumatic and non-traumatic lesions of the spinal cord including prevention, basic and clinical research, medical and surgical management, clinical practice, medical and surgical management, education, rehabilitation and social reintegration. Through its medical and multi-disciplinary team of Professionals, ISCoS endeavours to foster education, research and clinical excellence.
About NervGen
NervGen (TSXV: NGEN) (OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. The Company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis. For more information, go to
About NVG-291
NervGen holds the exclusive worldwide rights to NVG-291 and is developing a unique new class of drugs around the technology. NVG-291 is a therapeutic peptide that mimics the intracellular domain of the receptor protein tyrosine phosphatase sigma (PTPσ), a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs). Both PTPσ and CSPGs have been shown to inhibit neural repair mechanisms following nervous system damage. NVG-291-R, the rodent form of NVG-291, has been shown to promote functional recovery and enable nervous system repair in a range of animal models, including models of spinal cord injury, peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration, and remyelination.
For further information, please contact:
Huitt Tracey, Corporate Communications
Nancy Thompson, Vorticom Public Relations
Follow NervGen on Twitter, LinkedIn, and Facebook for the latest news on the Company.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “trend”, “indication”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the presentations at the MHSRS and ISCoS Annual Scientific Meeting; the Company’s initial target indications; and the creation of innovative treatments that enable the nervous system to repair itself following damage.
Forward-looking statements are based on estimates and assumptions made by the Company in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: the Company’s ability to manage the effects of the COVID-19 pandemic; the accuracy of the Company’s financial projections; the Company obtaining positive results in its clinical and other trials; the Company obtaining necessary regulatory approvals; and general business, market and economic conditions.
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, the impact of the COVID-19 pandemic, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the “Risk Factors” section of the Company’s Annual Information Form, Short Form Base Shelf Prospectus, financial statements and Management Discussion and Analysis which can be found on All clinical development plans are subject to additional funding.
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit
Related Quotes
Immunocore Holdings plc (NASDAQ: IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types. Fifty-five patients have been treated across ten dose cohorts. IMC-F106C was well-tolerated, with treatment-related adverse events that were manageable and consistent with the mechanism of action. In the clinically active dose cohorts, durable partial responses (
If you had Covid recently, you might be better off waiting. Important factors are your risk tolerance and health profile.
Artificial sweeteners are linked to higher risk of heart disease and stroke, a new study finds—specifically, aspartame, acesulfame potassium, and sucralose.
Story at a glance Under the 2010 Affordable Care Act, employers are required to provide full coverage for certain preventive services. However, a new ruling out of Texas found coverage of certain services, like pre-exposure prophylaxis (PrEP), violates employers’ rights under the Religious Freedom Restoration Act. Should this decision be upheld, experts say it will…
A new therapy for metastatic melanoma was shown to be more effective than a leading immunotherapy for the skin cancer.
Vascular dementia is the second most common form of dementia after Alzheimer's disease, affecting roughly one in 10 dementia patients. It occurs when other underlying conditions disrupt blood flow to the brain, resulting in inadequate oxygen and nutrients. "Inadequate blood flow can damage and eventually kill cells anywhere in the body, but the brain is especially vulnerable," explains the Alzheimer's Association.Many factors can put you at heightened risk for vascular dementia, including diabet
As the highly transmissible omicron variant continues to spread, health officials are recommending people receive updated COVID boosters to help fight infection. Over the last two years, the virus has continued to mutate, which means vaccine makers are constantly working to create new formulations. …
ALBANY, N.Y. — New York declared a state of emergency on Friday to boost vaccinations against polio. Gov. Kathy Hochul issued an executive order expanding the state’s network of vaccine administrators to EMS workers, midwives and pharmacists as evidence mounts that the once rare virus is spreading in the state. Only one case of paralytic polio has been recorded in Rockland County so far, but …
Yahoo Finance health reporter Anjalee Khemlani explains why Gov. Kathy Hochul is declaring a state of emergency in New York due to polio cases and also provides the latest update on monkeypox.
Get informed before you get the jab.
These common behaviors may lead to cardiovascular issues. Here's what to watch out for.
CLAIM: A federal court order in the legal dispute over government documents held by former President Donald Trump shows President Joe Biden ordered the FBI search at Trump’s Florida home. THE FACTS: While Monday's court order from U.S. District Judge Aileen Cannon does include the phrase “as requested by the incumbent president” it’s not related to last month’s search at Mar-a-Lago. The phrase comes from a May letter from the National Archives denying Trump’s request to delay turning over documents to the FBI.
Polio is now considered an official disaster in New York state after Gov. Kathy Hochul issued an executive order on Friday, following the discovery of the virus that causes polio in the wastewater of yet another county, according to state health officials. The order increases additional resources to help boost immunization efforts against the paralytic disease, the officials said. “On polio, we simply cannot roll the dice,” said Dr. Mary T. Bassett, New York State Health Commissioner.
Novartis AG (NYSE: NVS) has announced results from a new pooled exploratory analysis of the MONALEESA Phase 3 program of Kisqali + endocrine therapy (ET) in advanced breast cancer patients. In a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer, Kisqali + ET confirmed nearly one year of additional overall survival (OS) benefit. This subgroup analysis found that patients with visceral metas
In a safety notice, the FDA has received several reports of certain cancers in the scar tissue around breast implants. The FDA learned about these reports through continual postmarket reviews of breast implants and ongoing collaboration with external stakeholders. As of Sept. 1, 2022, the FDA had received ten reports about squamous cell carcinoma, a type of skin cancer, and 12 reports about various lymphomas related to breast implants. Right now, we do not have enough information to say whether
New York Gov. Kathy Hochul has declared a state of emergency over polio. And the first U.S. cases reported in almost a decade have sparked plenty of questions.
(Bloomberg) — Bitcoin rallied the most since July, breaking out of the narrowest trading range in about two years, as a drop in the dollar renewed demand for battered risk assets worldwide. Most Read from BloombergRussia Confirms Flight of Troops From Ukraine’s Kharkiv AreaCharles Becomes King as the Face of a Nation ChangesUkraine Army’s Breakthrough in North Threatens Russian GripUkraine Latest: Zelenskiy Warns of Winter as Russians Pull BackForced Buying Puts a Floor Under Stocks Nobody Else
Also in August, Kraft Heinz recalled 5,760 cases of its Wild Cherry flavored Capri Sun juice pouches, or about 230,000 juice pouches, that may have been accidentally contaminated with cleaning solution. Kraft Heinz became aware of the contamination after consumers called to complain about the strange taste of the drinks. Consumers who believe they may have purchased contaminated pouches may contact Kraft Heinz at 800-280-8252 to arrange a reimbursement.
The Relative Strength (RS) Rating for Gilead Sciences entered a new percentile Friday, with a rise from 78 to 84. Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. Gilead Sciences is working on a long consolidation with a 74.22 buy point.
Apple has been an American success story several times over with the Mac, iPod, iPhone and other inventions. But is Apple stock a buy now?


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort